📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 23:38
646 analysed today
646
Today
133,535
All-time analysed
40,118
Positive
6,284
Negative
79,315
Neutral
7,750
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
49 announcements match the current filters (relevance ≥ 5).
AHCL to acquire stakes in Apiqo Organics & Bizotic Lifescience for ₹153.30 Cr via share swap
Anlon Healthcare Limited has issued an AGM notice seeking shareholder approval for a ₹153.30 Cr acquisition of minority stakes in two companies via a preferential share swap. AHCL plans to issue up to 8.59 Cr equity shares at ₹17.85 per share (face value ₹2 plus ₹15.85 premium). Specifically, it will acquire a 44.94% stake in Apiqo Organics Private Limited for ₹116.52 Cr and a 47.41% stake in Bizotic Lifescience Private Limited for ₹36.78 Cr. Additionally, the company proposes to hike its authorized share capital from ₹110 Cr to ₹130 Cr.
Confidence: HIGH
What changedAHCL is initiating a ₹153.30 Cr share swap to acquire substantial minority stakes (44.94% and 47.41%) in two pharma companies, Apiqo Organics and Bizotic Lifescience.
Why it mattersThe acquisitions align with AHCL's strategic inorganic expansion to diversify its API manufacturing capabilities and scale up operations toward its target revenue base.
Total deal value: ₹153.30 CrIssue price per share: ₹17.85Apiqo Organics stake acquired: 44.94%Bizotic Lifescience stake acquired: 47.41%Authorized capital post-hike: ₹130.00 Cr
📅 Short termMarket sentiment may focus on the equity dilution from issuing ~8.59 Cr shares against the strategic value of the target assets.
📈 Long termIf successfully integrated, these acquisitions will expand AHCL's operating capacity and support its long-term API revenue growth targets.
⚠ Risk flags
- Equity dilution from issuing 8.59 Cr new shares
- Minority stake acquisition (<50% control) in both target entities
- Execution and integration risks associated with target businesses
Key Highlights
Preferential allotment of up to 8,58,83,617 equity shares at ₹17.85 per share, totaling up to ₹153.30 Cr for non-cash consideration.
Acquisition of 44.94% stake (45,16,200 shares) in Apiqo Organics Private Limited for ₹116.52 Cr via issuance of 6,52,76,283 shares.
Acquisition of 47.41% stake (22,99,000 shares) in Bizotic Lifescience Private Limited for ₹36.78 Cr via issuance of 2,06,07,334 shares.
Increase in Authorized Share Capital from ₹110 Cr (55 Cr shares) to ₹130 Cr (65 Cr shares).
13th Annual General Meeting scheduled for September 05, 2026 to seek shareholder approval.
👀 What to Watch
Track shareholder voting results at the September 05, 2026 AGM and subsequent regulatory approvals for the preferential issue and consolidation of target companies' financials.
AHCL to acquire stakes in AOPL and BLPL for ₹153.3 Cr via share swap; Record Date Aug 28
Anlon Healthcare Limited (AHCL) has approved the acquisition of a 44.94% stake in Apiqo Organics (AOPL) for ₹116.52 Cr and a 47.41% stake in Bizotic Lifescience (BLPL) for ₹36.78 Cr. The total consideration of ₹153.3 Cr will be settled via a preferential issue of 8.58 crore shares at ₹17.85 per share, which is a premium to the current market price of ₹14.2. This inorganic expansion is massive, representing ~127% of the company's FY25 revenue of ₹120 Cr. The board also approved increasing the authorized share capital to ₹130 Cr to facilitate this issuance.
Confidence: HIGH
What changedAHCL is shifting from a standalone operation to a larger group structure by acquiring significant minority stakes in two entities through a non-cash share swap agreement.
Why it mattersThe acquisition value of ₹153.3 Cr is larger than the company's entire FY25 revenue base (₹120 Cr), signaling an aggressive inorganic growth strategy to reach its FY27 target of ₹360-400 Cr.
Total Acquisition Value: ₹153.3 CrAcquisition vs FY25 Revenue: ~127%Preferential Issue Price: ₹17.85Shares to be Issued: 8,58,83,617Record Date: 28-Aug-2026
📅 Short termThe market is likely to react positively to the acquisition and the fact that the preferential issue is priced at a premium (₹17.85) to the current market price (₹14.2).
📈 Long termIf successfully integrated, these acquisitions could significantly accelerate AHCL's path toward its ₹400 Cr revenue target by FY27, though high equity dilution and initial losses in acquired entities are structural hurdles.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution from the issuance of 8.58 Cr new shares
- Target entity AOPL reported a loss of ₹4.89 Cr for FY26
- Related party transactions involved as promoters have interests in the target entities
Key Highlights
Acquisition of 44.94% stake in Apiqo Organics Private Limited for a consideration of ₹116.52 Cr
Acquisition of 47.41% stake in Bizotic Lifescience Private Limited for a consideration of ₹36.78 Cr
Issuance of 8,58,83,617 equity shares on a preferential basis at ₹17.85 per share
Authorized share capital increased from ₹110 Cr to ₹130 Cr to accommodate the new issuance
Record date for the Annual General Meeting and e-voting set for August 28, 2026
👀 What to Watch
Investors should monitor the shareholder approval process at the AGM on September 5, 2026, and watch for the financial integration of these entities, particularly noting that AOPL reported a loss of ₹4.89 Cr in FY26.
₹153.3 Cr Acquisitions: AHCL to acquire stakes in Apiqo Organics and Bizotic Lifescience
Anlon Healthcare Limited (AHCL) has approved the acquisition of significant minority stakes in two entities: 44.94% of Apiqo Organics Private Limited for ₹116.52 crore and 47.41% of Bizotic Lifescience Private Limited for ₹36.78 crore. These acquisitions will be executed via a share swap, involving the issuance of 8.59 crore equity shares at a price of ₹17.85 per share. Additionally, the board approved a material related-party transaction with Anlon Medicos Private Limited valued at ₹50 crore, representing 28.33% of the company's turnover. To facilitate this, the authorized share capital is being increased from ₹110 crore to ₹130 crore.
Confidence: HIGH
What changedAHCL is shifting from a single-unit operation to a group structure by acquiring large stakes in two pharmaceutical entities through a massive equity issuance.
Why it mattersThis move is a core part of AHCL's strategy to triple capacity and reach a revenue target of ₹360-400 crore by FY27, though it involves significant equity dilution and exposure to loss-making related parties.
Total Acquisition Value: ₹153.3 CrPreferential Issue Price: ₹17.85 per shareRPT Value vs Turnover: 28.33%New Authorized Capital: ₹130 CrShares to be Issued: 8,58,83,617 units
📅 Short termThe market may react to the preferential issue price of ₹17.85, which is a premium over the current market price of ₹14.2, potentially signaling internal valuation confidence.
📈 Long termIf successfully integrated, these acquisitions could provide the manufacturing base needed for AHCL's 200%+ growth target; however, the high level of related-party transactions requires long-term monitoring.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution from the issuance of 8.59 crore new shares
- Related party (Anlon Medicos) has a negative net worth of ₹4.33 crore and FY26 loss of ₹4.89 crore
- High concentration of related-party transactions (28.33% of turnover)
Key Highlights
Acquisition of 44.94% stake in Apiqo Organics for a purchase consideration of ₹116.52 crore.
Acquisition of 47.41% stake in Bizotic Lifescience for a purchase consideration of ₹36.78 crore.
Issuance of 8,58,83,617 equity shares on a preferential basis at ₹17.85 per share (totaling ~₹153.3 crore).
Authorized share capital increased by ₹20 crore to a new limit of ₹130 crore.
Approval of a ₹50 crore related-party transaction with Anlon Medicos, which reported a loss of ₹4.89 crore in FY26.
👀 What to Watch
Investors should monitor the upcoming AGM on September 5, 2026, for shareholder approval of these acquisitions and the subsequent impact on consolidated margins as the company integrates these entities.
AHCL to Acquire 44.94% of Apiqo Organics and 47.41% of Bizotic Lifescience via Share Swap
Anlon Healthcare Limited (AHCL) has revised its acquisition terms to acquire a 44.94% stake in Apiqo Organics (AOPL) and a 47.41% stake in Bizotic Lifescience (BLPL). The transaction is structured as a share swap, issuing up to 8.59 crore equity shares at a price of Rs 17.85 per share. The combined FY26 turnover of the two target entities is approximately Rs 103.8 crore, which represents about 86% of AHCL's FY25 revenue of Rs 120 crore. These are related-party transactions aimed at securing the supply of critical pharmaceutical intermediates and APIs.
Confidence: HIGH
What changedThe company corrected the acquisition percentages from 32.52% to 44.94% for AOPL and from 43.33% to 47.41% for BLPL, while disclosing full deal terms including swap ratios.
Why it mattersThis is a significant vertical integration move that secures intermediate supply, supporting the company's target to triple revenue to Rs 360-400 crore by FY27.
AOPL Acquisition Stake: 44.94%BLPL Acquisition Stake: 47.41%Combined Target Turnover (FY26): Rs 103.81 crIssue Price per Share: Rs 17.85Target Turnover vs AHCL FY25 Revenue: ~86%
📅 Short termThe market is likely to view the scale of the acquisition positively, though the significant equity dilution from the share swap may cause some price volatility.
📈 Long termThe acquisition aligns with the 'China+1' strategy by bringing intermediate manufacturing in-house, potentially improving margins and supply chain reliability over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution (8.59 crore shares)
- Related-party transaction involving common promoters
- Integration risk of two separate private entities
Key Highlights
Acquisition of 44.94% in Apiqo Organics (AOPL) and 47.41% in Bizotic Lifescience (BLPL)
AOPL reported a turnover of Rs 72.54 crore for FY26 and Rs 45.54 crore for Q1 FY27
BLPL reported a turnover of Rs 31.27 crore for FY26 and Rs 11.53 crore for Q1 FY27
Total consideration for AOPL acquisition is approximately Rs 116.52 crore
Issuance of up to 8,58,83,617 equity shares at a fixed price of Rs 17.85 per share
👀 What to Watch
Investors should monitor the 90-day execution timeline for the share swap and watch for the impact on consolidated margins as these related-party entities are integrated into the supply chain.
AHCL Q1 FY27 Revenue Jumps 163% to ₹87.62 Cr; EBITDA Margins Moderate to 17%
Anlon Healthcare (AHCL) reported a massive 163% YoY increase in consolidated revenue to ₹87.62 Cr for Q1 FY27, largely due to the consolidation of the Remember India Health links acquisition. EBITDA margins moderated to 17% from previous highs, impacted by a 2-3x spike in raw material costs and the turnaround phase of new subsidiaries. Management has guided for a margin recovery to 25-30% in Q2/Q3 FY27 as price revisions take effect. The company has significantly scaled its manufacturing capacity to 1,400-1,600 MTPA, marking its transition into an integrated pharmaceutical platform.
Confidence: HIGH
What changedAHCL has transitioned from a pure API/Intermediate manufacturer to an integrated pharmaceutical player with a presence in finished dosages and a significantly larger manufacturing base.
Why it mattersThe successful consolidation of acquisitions has nearly tripled the revenue base, but the high working capital cycle (130+ days) and margin pressure from raw materials remain key operational challenges to solve for sustainable profitability.
Q1 FY27 Revenue: ₹87.62 CrYoY Revenue Growth: 163%EBITDA Margin: 17%Total Capacity: 1,400-1,600 MTPADebt: ₹70 CrReceivable Days: 130-135 days
📅 Short termThe stock may react to the strong top-line growth, though the margin compression and high receivables are near-term headwinds that require monitoring over the next 1-2 quarters.
📈 Long termThe structural shift to an integrated model and 30% revenue CAGR target suggests significant scale-up potential if the company successfully navigates the 'China+1' strategy and regulated market audits.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High working capital intensity with 130-135 days receivables
- Raw material price volatility (2-3x increase in solvents/petroleum products)
- Integration risks associated with multiple recent acquisitions
Key Highlights
Consolidated Total Income surged to ₹87.62 Cr in Q1 FY27 compared to ₹33.31 Cr in Q1 FY26.
EBITDA margins compressed to 17% due to raw material prices increasing 2-3x and acquisition integration costs.
Total manufacturing capacity expanded to 1,400-1,600 MTPA following the acquisitions of Apiqo and Bizotic.
Debt levels stood at ₹70 Cr with an average interest cost of 8.5% to 8.6%.
Receivable days remain high at 130-135 days, though management is tightening payment terms to improve cash flow.
👀 What to Watch
Watch for EBITDA margin recovery in the upcoming Q2 results to verify if price hikes successfully offset raw material volatility. Monitor the integration of the finished dosage formulation (FDF) business as a new growth lever.
AHCL to Acquire Stakes in AOPL and BLPL via Rs 116.52 Cr Share Swap
Anlon Healthcare Limited (AHCL) has executed Share Swap Agreements to acquire up to 32.52% of Apiqo Organics Private Limited (AOPL) and 43.33% of Bizotic Lifescience Private Limited (BLPL). The acquisition of the AOPL stake is valued at Rs 116.52 Cr, to be settled by issuing AHCL shares at Rs 17.85 per share. Both targets are related parties, with AOPL reporting a turnover of Rs 72.54 Cr in FY26. The transaction involves the issuance of up to 8.58 crore new equity shares, representing a significant expansion and equity dilution for the company.
Confidence: HIGH
What changedAHCL is moving to acquire significant minority stakes in two related-party pharmaceutical companies to secure its supply chain and expand into CRAMS.
Why it mattersThe acquisition cost for the AOPL stake alone is nearly 97% of AHCL's FY25 revenue, indicating a massive scale-up but also substantial equity dilution and related-party risk.
AOPL Acquisition Value: Rs 1,165,179,600Issue Price per Share: Rs 17.85Max Shares to be Issued: 8,58,83,617AOPL FY26 Turnover: Rs 7,254.11 LakhBLPL FY26 Turnover: Rs 3,126.64 LakhAOPL Value vs FY25 Revenue: ~97%
📅 Short termThe stock may experience volatility as the market digests the massive equity dilution (8.58 Cr shares) and the related-party nature of the transaction.
📈 Long termIf integrated successfully, these acquisitions could help AHCL reach its FY27 revenue target of Rs 360-400 Cr by securing intermediates and adding API manufacturing capacity.
⚠ Risk flags
- Significant equity dilution
- Related-party transaction with common promoters
- AOPL is a recently incorporated entity (December 2025)
Key Highlights
Acquisition of up to 32.52% stake in AOPL and 43.33% stake in BLPL via share swap
Total issuance of up to 8,58,83,617 fresh equity shares at an issue price of Rs 17.85 each
AOPL acquisition cost valued at approximately Rs 116.52 Cr
AOPL FY26 turnover of Rs 72.54 Cr is significant compared to AHCL FY25 revenue of Rs 120 Cr
Transaction expected to be completed within 90 days subject to regulatory approvals
👀 What to Watch
Investors should monitor the upcoming shareholder meeting for approval and the final valuation report to ensure the swap ratio is fair. The key metric to watch is the post-allotment EPS dilution versus the projected revenue synergies from these related-party entities.
AHCL Targets ₹400 Cr Revenue by FY27; Capacity Reaches 1,600 MTPA via Acquisitions
Anlon Healthcare (AHCL) has outlined a transformational growth path following the acquisition of three companies: Bizotic Lifescience, Apiqo Organics, and Remember India Health Links for a combined ~₹14.57 crore. These acquisitions have expanded the company's total installed capacity to 1,400-1,600 MTPA, supporting a revenue target of ₹360-400 crore by FY27, up from ₹120 crore in FY25. The company is successfully shifting its mix toward higher-margin APIs, which now account for 50.32% of Q1 FY27 revenue compared to 22.17% a year ago. Regulatory momentum is building with 21 DMF filings and pending approvals from EDQM (Europe) and ANVISA (Brazil).
Confidence: HIGH
What changedAHCL has transitioned from a standalone API manufacturer to an integrated pharmaceutical group with three new subsidiaries and a significantly larger manufacturing base.
Why it mattersThe expansion and backward integration through Apiqo Organics reduce supply chain risks from China, while the entry into formulations via Remember India improves margin potential and market reach.
Total Projected Capacity: 1,400-1,600 MTPAFY27 Revenue Target: ₹360-400 CrTotal Acquisition Cost (3 units): ₹14.57 CrAPI Revenue Share (Q1 FY27): 50.32%Global DMF Filings: 21
📅 Short termThe market is likely to react positively to the aggressive growth targets and the successful completion of the M&A cycle, which provides immediate scale.
📈 Long termIf AHCL achieves its FY27 revenue targets and clears international regulatory audits, it could structurally re-rate from a small-scale intermediate player to a mid-sized integrated API/FDF exporter.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High product concentration (Top 5 products = 78% revenue)
- Integration risk of three simultaneous acquisitions
- Exposure to Chinese raw material price volatility
Key Highlights
Total installed capacity expanded to 1,400-1,600 MTPA following three strategic acquisitions in 2026.
Revenue guidance set at ₹360-400 crore for FY27, representing a ~30% CAGR over three years.
API segment revenue contribution jumped to 50.32% in Q1 FY27 from 22.17% in Q1 FY26.
Acquired 63.98% stake in Remember India Health Links for ₹5.38 crore to enter the Finished Dosage Formulations (FDF) market.
Filed 21 Drug Master Files (DMFs) globally, with key approvals pending for Ketoprofen and Loxoprofen in Europe and Brazil.
👀 What to Watch
Investors should monitor the successful integration of the three new subsidiaries and the timeline for regulatory approvals from USFDA and EDQM, which are essential for the company's high-margin export strategy.
163% Revenue Growth in Q1 FY27; AHCL Reports ₹8.28 Cr PAT and Entry into FDF Segment
Anlon Healthcare (AHCL) reported a massive 163.02% YoY increase in total income to ₹87.62 Cr for Q1 FY27. EBITDA grew 150.14% to ₹15.65 Cr, while PAT rose 133.13% to ₹8.28 Cr. A key strategic milestone was the completion of a 63.98% stake acquisition in Remember India Health Links for ₹5.38 Cr, marking AHCL's entry into the Finished Dosage Formulations (FDF) segment. Management has guided for a 30% revenue CAGR over the next three years with EBITDA margins sustained between 25-30%.
Confidence: HIGH
What changedAHCL has transitioned from a pure API and intermediate manufacturer to an integrated pharmaceutical player by entering the Finished Dosage Formulations (FDF) segment through acquisition.
Why it mattersThe shift to FDF and regulated markets is designed to capture 15-17% higher margins compared to domestic API sales and de-risk the business from Chinese import price volatility.
Q1 FY27 Total Income: ₹87.62 CrYoY Income Growth: 163.02%Q1 FY27 PAT: ₹8.28 CrAcquisition Cost (Remember India): ₹5.38 CrQ1 Revenue vs FY25 Annual Revenue: ~73%
📅 Short termThe stock is likely to react positively to the triple-digit growth in both top and bottom lines and the successful completion of the FDF acquisition.
📈 Long termThe company is on a high-growth trajectory aiming for ₹360-400 Cr revenue by FY27; structural integration of APIs and Formulations could lead to significant re-rating if margin targets are met.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High client concentration (top 5 products contribute 78% of revenue)
- Dependency on Chinese imports for domestic market intermediates
- Execution risk in scaling the newly acquired FDF business
Key Highlights
Total Income surged 163.02% YoY to ₹87.62 Cr in Q1 FY27 from ₹33.31 Cr in Q1 FY26
EBITDA increased by 150.14% to ₹15.65 Cr, reflecting strong operational scaling
Completed acquisition of 63.98% stake in Remember India Health Links Pvt. Ltd. for ₹5.38 Cr on May 8, 2026
Gained access to 30+ formulation dossiers, enabling entry into tablets and capsules markets
Management maintains long-term guidance of 30% revenue CAGR and 25-30% EBITDA margins
👀 What to Watch
Monitor the commercialization of the 700 MTPA capacity expansion expected by Q3 FY27 and the successful integration of the FDF segment. Investors should also track the progress of USFDA and EDQM audits which are critical for higher-margin regulated market exports.
AHCL Q1 PAT Grows 35% YoY to ₹4.8 Cr; Board Approves Subsidiary Acquisitions via Share Swap
Anlon Healthcare Limited (AHCL) reported a 35.2% YoY increase in Net Profit to ₹4.80 Cr for Q1 FY27, although revenue from operations saw a 6.9% YoY decline to ₹30.98 Cr. Sequentially, the performance was significantly lower than Q4 FY26, where revenue was ₹55.42 Cr and PAT was ₹9.79 Cr. The Board has approved acquiring the remaining stakes in Apiqo Organics (32.52%) and Bizotic LifeScience (43.33%) through a preferential share swap to make them wholly-owned subsidiaries. The company also confirmed that the entire ₹121.03 Cr raised through its IPO has been fully utilized.
Confidence: HIGH
What changedAHCL reported its Q1 FY27 financial results and initiated a corporate restructuring to fully own two subsidiary entities via a non-cash share swap arrangement.
Why it mattersThe consolidation of subsidiaries simplifies the corporate structure and allows for better operational control, while the full utilization of IPO funds indicates the completion of the primary investment phase for their growth strategy.
Revenue (Q1 FY27): ₹30.98 CrNet Profit (Q1 FY27): ₹4.80 CrYoY PAT Growth: 35.2%IPO Proceeds Utilized: ₹121.03 CrStake to acquire in AOPL: 32.52%Stake to acquire in BLPL: 43.33%
📅 Short termThe sequential decline in revenue and profit (QoQ) may lead to short-term price volatility, though the consolidation of subsidiaries is a positive strategic move.
📈 Long termThe company's long-term trajectory depends on successfully tripling its capacity to 1,100 MTPA and obtaining USFDA/European regulatory approvals to increase high-margin export shares.
⚠ Risk flags
- Significant sequential decline in revenue and profit compared to Q4 FY26
- High client concentration with top 5 products contributing 78% of revenue
- Pricing pressure in domestic markets due to Chinese competition
Key Highlights
Net Profit increased to ₹4.80 Cr in Q1 FY27 from ₹3.55 Cr in Q1 FY26, a growth of 35.2%.
Revenue from operations fell to ₹30.98 Cr in Q1 FY27 from ₹33.30 Cr in the year-ago period.
Board approved share swap to acquire 32.52% of Apiqo Organics and 43.33% of Bizotic LifeScience.
Total IPO proceeds of ₹121.03 Cr fully utilized, including ₹30.72 Cr for manufacturing facility expansion.
Finance costs increased to ₹0.96 Cr in Q1 FY27 compared to ₹0.82 Cr in Q1 FY26.
👀 What to Watch
Monitor the operational integration of the two new wholly-owned subsidiaries and the timeline for the 700 MTPA capacity expansion, which is vital for achieving the management's FY27 revenue target of ₹360-400 Cr.
AHCL PAT Up 35% YoY; Board Approves M&A to Create Wholly Owned Subsidiaries
Anlon Healthcare Limited (AHCL) reported Q1 FY27 results with a 35% YoY increase in PAT to ₹4.80 cr, despite a 7% YoY decline in revenue to ₹30.98 cr. Sequentially, revenue saw a sharp 44% drop from ₹55.42 cr in Q4 FY26. The Board approved acquiring the remaining stakes in Apiqo Organics (32.52%) and Bizotic LifeScience (43.33%) via a share swap to make them wholly-owned subsidiaries. Additionally, the company confirmed 100% utilization of its ₹121.03 cr IPO proceeds, primarily for capex and working capital.
Confidence: HIGH
What changedAHCL is consolidating its corporate structure by acquiring minority stakes in two entities via share swap and has completed the deployment of all IPO funds.
Why it mattersThe move to wholly-owned subsidiaries simplifies the group structure and allows for full capture of subsidiary profits. Completing IPO capex signals that the company is entering the operational phase of its capacity expansion strategy.
Revenue (Q1 FY27): ₹30.98 crPAT (Q1 FY27): ₹4.80 crYoY PAT Growth: 35.2%IPO Proceeds Utilized: ₹121.03 crQoQ Revenue Growth: -44.1%
📅 Short termThe market may react positively to the PAT growth and M&A consolidation, though the sharp sequential revenue decline warrants caution.
📈 Long termStructural shift towards a larger consolidated entity with expanded capacity (targeting 1,100 MTPA) and increased export focus could re-rate the business if execution stays on track.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from share swap
- Significant sequential revenue volatility
- High client concentration (top 5 products = 78% revenue)
Key Highlights
Profit After Tax (PAT) grew 35.2% YoY to ₹4.80 cr in Q1 FY27 from ₹3.55 cr in Q1 FY26.
Revenue from operations declined 7% YoY to ₹30.98 cr and fell 44% on a sequential basis.
Board approved share swap to acquire 32.52% of Apiqo Organics and 43.33% of Bizotic LifeScience.
Full utilization of ₹121.03 cr IPO proceeds achieved, including ₹30.72 cr for manufacturing expansion.
Other expenses increased significantly to ₹2.94 cr from ₹1.61 cr in the same quarter last year.
👀 What to Watch
Investors should monitor the equity dilution impact from the share swap and the integration timeline for the two new wholly-owned subsidiaries. Watch for the commercialization of the 700 MTPA capacity expansion expected by Q3 FY27.
AHCL Acquires 65% Stake in New Subsidiary Anlon Biologics for Medical Devices and Biosimilars
Anlon Healthcare Limited (AHCL) has incorporated a new subsidiary, Anlon Biologics Private Limited, effective July 10, 2026. AHCL holds a 65% controlling stake in the entity, acquired for a cash consideration of ₹6.5 lakhs. The new subsidiary is positioned to manufacture surgical implants, medical devices, peptides, and biosimilars. This move is a strategic diversification to complement AHCL's existing pain management segment and enter high-growth biological sectors.
Confidence: HIGH
What changedAHCL has officially expanded its corporate structure by forming a majority-owned subsidiary to enter the medical devices and biologics market.
Why it mattersThis represents a strategic shift from pure API manufacturing toward higher-value medical devices and biosimilars, potentially diversifying revenue streams and improving long-term margins.
Investment Amount: ₹6.5 lakhsStake Acquired: 65%Subsidiary Paid-up Capital: ₹10 lakhsIncorporation Date: July 10, 2026
📅 Short termThe announcement is sentimentally positive as it shows growth intent, though the immediate financial impact is negligible given the small initial investment.
📈 Long termIf successfully executed, the foray into biosimilars and medical devices could structurally transform the company's profile from a commodity API player to a specialized healthcare entity.
⚠ Risk flags
- Execution risk in entering complex new segments like biosimilars
- Regulatory hurdles associated with medical device manufacturing
- Small initial capital base relative to the high capex requirements of biologics
Key Highlights
Incorporated Anlon Biologics Private Limited on July 10, 2026, as a 65%-owned subsidiary.
AHCL invested ₹6.5 lakhs to subscribe to 65,000 equity shares at a face value of ₹10 each.
The subsidiary has an authorized and paid-up share capital of ₹10,00,000.
Target segments include surgical implants, medical devices, peptides, and biosimilars.
The move aims to leverage opportunities in the pain management segment and biological compositions.
👀 What to Watch
Investors should monitor the subsidiary's timeline for setting up manufacturing facilities and obtaining regulatory approvals for medical devices and biosimilars, as these are high-entry-barrier segments.
AHCL incorporates 55%-owned subsidiary for surgical implants and medical devices
Anlon Healthcare Limited (AHCL) has incorporated a new subsidiary, Anlon Medicare Private Limited, on July 09, 2026. AHCL holds a 55% stake in the new entity, having invested ₹11,00,000 for 1,10,000 equity shares. The subsidiary will focus on manufacturing surgical implants and medical devices, aiming to complement AHCL's existing pain management segment. While the initial investment is small relative to the company's scale, it marks a strategic diversification into the medical devices sector.
Confidence: HIGH
What changedAHCL has officially formed a 55%-owned subsidiary to enter the medical devices and surgical implants market.
Why it mattersIt diversifies the company's portfolio beyond APIs into medical devices, specifically targeting the pain management segment, which could offer different growth cycles and margins.
Investment Amount: ₹11,00,000Stake Acquired: 55%Authorized Capital: ₹50,00,000Investment vs Dec 2025 Revenue: ~0.31%
📅 Short termMinimal immediate impact as the subsidiary is newly incorporated and yet to commence business operations.
📈 Long termStrategic significance depends on the company's ability to execute in the medical devices space, which has different regulatory requirements than its core API business.
⚠ Risk flags
- Execution risk in a new business segment
- Potential for future capital requirements
Key Highlights
Incorporated Anlon Medicare Private Limited with a 55% majority stake on July 09, 2026
Initial cash investment of ₹11,00,000 for 1,10,000 equity shares at ₹10 each
Subsidiary has an authorized share capital of ₹50,00,000 and paid-up capital of ₹20,00,000
New business line focuses on surgical implants and medical devices for the pain management segment
👀 What to Watch
Monitor the timeline for the commencement of operations and any future capital expenditure requirements for the new subsidiary's manufacturing facility.
AHCL to Incorporate Two New Subsidiaries for Medical Devices and Biologics Expansion
Anlon Healthcare Limited (AHCL) has approved the incorporation of two new subsidiaries, Anlon Medicare and Anlon Biologics, to diversify into surgical implants and peptide manufacturing. The company will invest Rs 11 lakh for a 55% stake in Anlon Medicare and Rs 6.5 lakh for a 65% stake in Anlon Biologics. This move aligns with AHCL's strategy to expand beyond its core API business into higher-margin segments like medical devices and biosimilars. Additionally, the company is rebranding an existing subsidiary to Anlon Medicos Private Limited.
Confidence: HIGH
What changedAHCL is expanding its corporate structure by creating two new specialized subsidiaries for medical devices and biologics, moving beyond its traditional API focus.
Why it mattersThe expansion into biologics and medical devices represents a strategic shift toward higher-value healthcare segments, which is critical for achieving the company's ambitious FY27 revenue target of Rs 360-400 Cr.
Investment in Anlon Medicare: Rs 11,00,000Investment in Anlon Biologics: Rs 6,50,000Stake in Medicare Subsidiary: 55%Stake in Biologics Subsidiary: 65%Dec 2025 Quarterly Revenue: Rs 35.578 cr
📅 Short termThe market may view the diversification positively as a long-term growth signal, though the small initial capital outlay means no immediate impact on financials.
📈 Long termIf successful, the entry into biologics and medical devices could structurally improve margins and reduce the company's vulnerability to Chinese API price competition.
⚠ Risk flags
- Execution risk in entering highly regulated new segments like Biologics
- Significant future capital expenditure will likely be required beyond the initial subscription
Key Highlights
Investment of Rs 11,00,000 for a 55% stake in the new subsidiary Anlon Medicare Private Limited
Investment of Rs 6,50,000 for a 65% stake in the new subsidiary Anlon Biologics Private Limited
Strategic entry into surgical implants and medical devices to complement the pain management segment
Entry into the high-growth peptides and biosimilars market through Anlon Biologics
Rebranding of 'Remember India Health Links Private Limited' to 'Anlon Medicos Private Limited'
👀 What to Watch
Investors should monitor the timeline for the commencement of operations in these new subsidiaries and watch for future capex announcements related to manufacturing facilities for these segments.
Anlon Healthcare FY26 PAT Rises 41.8% to ₹29.1 Cr; Targets ₹800 Cr Revenue by FY28
Anlon Healthcare delivered a strong FY26 performance with consolidated revenue growing 43% YoY to ₹172.22 crore and PAT increasing 41.8% to ₹29.09 crore. The company has provided aggressive forward-looking guidance, targeting ₹380-400 crore in revenue for FY27 and ₹700-800 crore for FY28, supported by the acquisitions of Apiqo Organics and Bizotic Life Science. Management is initiating a ₹130 crore Capex for standalone expansion, aiming for a 30% revenue CAGR over the next three years while maintaining EBITDA margins in the 24-25% range.
Key Highlights
FY26 consolidated revenue grew 42.98% YoY to ₹172.22 crore with a PAT of ₹29.09 crore.
Management guided for a significant revenue jump to ₹380-400 crore in FY27 and ₹700-800 crore in FY28.
Acquisitions of Apiqo Organics and Bizotic Life Science have expanded total capacity to 1400-1600 MTPA.
A new ₹130 crore Capex project is underway, expected to be operational by Q1 FY28 with a peak revenue potential of ₹450 crore.
The company plans to launch 7 new APIs and file 3-5 additional DMFs in FY27 to deepen regulated market penetration.
👀 What to Watch
Investors should focus on the company's ability to execute its massive capacity expansion and integrate acquisitions, as the ambitious FY28 revenue targets represent a nearly 4x growth from FY26 levels.
Anlon Healthcare Targets 30% Revenue CAGR and Quadruples Capacity via Strategic Acquisitions
Anlon Healthcare (AHCL) has outlined a robust growth trajectory in its FY26 investor presentation, projecting a 30% revenue CAGR over the next three years. The company successfully completed the acquisitions of Bizotic Lifescience and Apiqo Organics for a combined consideration of ₹9.19 crore, boosting total manufacturing capacity to 1,400-1,600 MTPA. Revenue mix has shifted significantly, with Pharmaceutical Intermediates now contributing 71.24% of total revenue compared to 35.70% in the previous year. The company is also diversifying into high-growth circular economy sectors, including e-waste management and lithium-ion battery recycling.
Key Highlights
Acquired majority stakes in Bizotic Lifescience (56.67%) and Apiqo Organics (67.48%) to expand capacity from 400 MTPA to 1,600 MTPA.
Guided for a 30% revenue CAGR over the next 3 years supported by 21 global DMF filings and 65 commercialized products.
Pharmaceutical Intermediates segment revenue share surged to 71.24% in FY26, up from 35.70% in FY25.
Received key regulatory approvals from EDQM (Europe), ANVISA (Brazil), and NMPA (China) for core API products.
Announced strategic entry into battery recycling (Li, Co, Ni, Mn recovery) and e-waste management to diversify the portfolio.
👀 What to Watch
Investors should focus on the company's ability to maintain margins while scaling capacity four-fold and monitor the execution of the new e-waste and battery recycling verticals. The aggressive 30% CAGR guidance suggests a strong growth outlook, provided the integration of recent acquisitions remains seamless.
Anlon Healthcare FY26 Results: Consolidated PAT up 42% to ₹29.09 Cr; Revenue grows 43%
Anlon Healthcare reported a strong financial performance for FY26, with consolidated total income rising 43% YoY to ₹172.22 crore. Profitability saw a significant boost as PAT increased by 41.77% to ₹29.09 crore, while EBITDA grew by 47.55% to ₹47.77 crore. The company successfully integrated acquisitions like Bizotic Lifescience and Apiqo Organics to strengthen its manufacturing and backward integration capabilities. Management has provided a robust outlook, targeting a 30% revenue CAGR over the next three years with EBITDA margins maintained between 25-30%.
Key Highlights
Consolidated Total Income grew 42.98% YoY to ₹172.22 Cr in FY26 compared to ₹120.46 Cr in FY25.
Consolidated PAT increased by 41.77% to ₹29.09 Cr, while EBITDA rose 47.55% to ₹47.77 Cr.
Management issued guidance for 30% revenue CAGR over the next three years with 25-30% EBITDA margins.
Completed the acquisition of Bizotic Lifescience and integrated Apiqo Organics to enhance supply-chain efficiency.
Advancing CDMO business with 3 molecules for global innovators and a total of 21 DMF filings to date.
👀 What to Watch
Investors should consider this a strong growth signal in the API and specialty chemical space, backed by solid margin guidance and strategic acquisitions. Monitor the company's ability to scale its CDMO vertical and maintain the projected 30% CAGR in a competitive global environment.
AHCL FY26 Revenue Jumps 46.7% to ₹176.5 Cr; Annual PAT Grows 35.5% to ₹27.8 Cr
Anlon Healthcare Limited (AHCL) reported a robust performance for the financial year ended March 31, 2026, with annual revenue from operations rising 46.7% YoY to ₹176.50 crore. Annual Profit After Tax (PAT) grew by 35.5% to ₹27.81 crore, despite a year-on-year decline in Q4 profit which stood at ₹9.79 crore compared to ₹16.65 crore in Q4 FY25. The company's balance sheet expanded significantly, with total assets nearly doubling to ₹317.21 crore, supported by an increase in equity share capital to ₹53.15 crore.
Key Highlights
Annual Revenue from Operations increased to ₹176.50 crore in FY26 from ₹120.29 crore in FY25.
Full-year Net Profit (PAT) rose 35.5% to ₹27.81 crore compared to ₹20.52 crore in the previous fiscal.
Quarter-on-quarter revenue growth was strong, with Q4 FY26 revenue at ₹55.42 crore vs ₹35.58 crore in Q3 FY26.
Total Assets grew to ₹317.21 crore from ₹181.30 crore, driven by higher inventories and trade receivables.
Earnings Per Share (EPS) for FY26 stood at ₹5.93 on an expanded equity base of ₹53.15 crore.
👀 What to Watch
Investors should view the strong annual growth and asset expansion as positive indicators of scaling operations. However, the decline in Q4 YoY profitability and the significant increase in trade receivables (₹104.17 crore) warrant closer monitoring of working capital efficiency.
Anlon Healthcare FY26 Revenue Jumps 46.7% to ₹176.5 Cr; PAT Up 35.5% to ₹27.8 Cr
Anlon Healthcare Limited (AHCL) reported a robust financial performance for the fiscal year ended March 31, 2026, with annual revenue from operations growing 46.7% YoY to ₹176.50 crore. Net profit for the full year increased by 35.5% to ₹27.81 crore, up from ₹20.52 crore in FY25. The fourth quarter (Q4 FY26) was particularly strong, with PAT nearly doubling to ₹9.79 crore compared to ₹5.15 crore in the year-ago period. However, annual EPS slightly declined to ₹5.93 from ₹6.37, reflecting equity dilution as the share capital increased from ₹39.85 crore to ₹53.15 crore.
Key Highlights
Annual Revenue from Operations increased by 46.7% YoY to ₹17,649.87 lacs in FY26.
Full-year Profit After Tax (PAT) rose 35.5% to ₹2,780.82 lacs compared to ₹2,051.79 lacs in FY25.
Q4 FY26 PAT surged 90% YoY to ₹979.20 lacs from ₹515.20 lacs in Q4 FY25.
Total Assets grew significantly by 75% to ₹31,720.50 lacs as of March 31, 2026.
Equity Share Capital expanded to ₹5,315.15 lacs from ₹3,985.15 lacs, indicating a capital raise during the fiscal year.
👀 What to Watch
Investors should view the strong top-line and bottom-line growth as a positive sign of operational scaling, though the slight EPS dilution due to increased share capital warrants monitoring for future earnings consistency.
Anlon Healthcare Completes Acquisition of 63.98% Stake in Remember India Health Links
Anlon Healthcare Limited (AHCL) has successfully completed the acquisition of a 63.98% equity stake in Remember India Health Links Private Limited as of May 8, 2026. This transaction follows the Share Purchase Agreement (SPA) previously executed on April 16, 2026. Consequently, Remember India Health Links has now become a subsidiary of AHCL. This move signifies a strategic expansion for the company into new healthcare segments or markets.
Key Highlights
Acquired a controlling 63.98% equity shareholding in Remember India Health Links Private Limited
The target company has officially become a subsidiary of Anlon Healthcare Limited effective May 8, 2026
Completion follows the execution of a Share Purchase Agreement dated April 16, 2026
The acquisition is in compliance with Section 179 of the Companies Act, 2013 and SEBI Listing Regulations
👀 What to Watch
Investors should monitor the upcoming quarterly results to assess the revenue and margin contribution from this new subsidiary. This acquisition indicates a growth-oriented strategy through inorganic expansion.
Anlon Healthcare Allots 26.57 Crore Bonus Shares in 1:1 Ratio
Anlon Healthcare Limited (AHCL) has finalized the allotment of 26,57,57,500 bonus equity shares of Rs. 2 each. The allotment was made in a 1:1 ratio to shareholders who held the stock as of the record date, April 24, 2026. This corporate action has effectively doubled the company's total number of outstanding equity shares to 53,15,15,000. Following this allotment, the paid-up equity share capital of the company has increased to Rs. 106.30 crore.
Key Highlights
Allotted 26,57,57,500 fully paid-up bonus equity shares of face value Rs. 2 each
Bonus issue executed in the proportion of 1:1 for eligible members
Total paid-up equity capital increased from Rs. 53.15 crore to Rs. 106.30 crore
Post-allotment, the total number of equity shares stands at 53,15,15,000
The record date for the bonus eligibility was fixed as April 24, 2026
👀 What to Watch
Investors should observe the increased liquidity in the stock and the proportional adjustment in the share price following the 1:1 bonus issue. No immediate action is required as the total investment value remains unchanged despite the higher share count.
